Zheng Y, Pan J, Wang J, Zhang J
World J Radiol. 2024; 16(9):482-488.
PMID: 39355392
PMC: 11440279.
DOI: 10.4329/wjr.v16.i9.482.
Ocana-Guzman R, Osorio-Perez D, Chavez-Galan L
Pharmaceuticals (Basel). 2023; 16(8).
PMID: 37631034
PMC: 10458516.
DOI: 10.3390/ph16081119.
Pilmis B, Kherabi Y, Huriez P, Zahar J, Mokart D
Cancers (Basel). 2023; 15(7).
PMID: 37046650
PMC: 10093532.
DOI: 10.3390/cancers15071989.
Xia S, Gong H, Wang Y, Liu L, Zhao Y, Guo L
Front Pharmacol. 2023; 14:1129730.
PMID: 37007042
PMC: 10050453.
DOI: 10.3389/fphar.2023.1129730.
Hiba Z, Abdelmoughit H, Zaynab I, Hounaida J, Rachida L, Youssef O
Radiol Case Rep. 2022; 17(10):3979-3981.
PMID: 36032207
PMC: 9411188.
DOI: 10.1016/j.radcr.2022.07.083.
Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids.
Sadek M, Loizidou A, Drowart A, van den Wijngaert S, Gomez-Galdon M, Aspeslagh S
J Immunother Precis Oncol. 2022; 3(1):27-30.
PMID: 35756180
PMC: 9208388.
DOI: 10.4103/JIPO.JIPO_23_19.
[Pneumocystis jirovecii Pneumonia in Patients with Lung Cancer: A Review].
Li T, Zhou J, Wang Q
Zhongguo Fei Ai Za Zhi. 2022; 25(4):272-277.
PMID: 35340199
PMC: 9051306.
DOI: 10.3779/j.issn.1009-3419.2022.101.14.
Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis.
Ando H, Suzuki K, Yanagihara T
Biomedicines. 2021; 9(10).
PMID: 34680601
PMC: 8533467.
DOI: 10.3390/biomedicines9101484.
Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy.
Morelli T, Fujita K, Redelman-Sidi G, Elkington P
Thorax. 2021; 77(3):304-311.
PMID: 34607905
PMC: 8867274.
DOI: 10.1136/thoraxjnl-2021-217260.
Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies.
Castelli V, Lombardi A, Palomba E, Bozzi G, Ungaro R, Alagna L
Cells. 2021; 10(9).
PMID: 34571876
PMC: 8467545.
DOI: 10.3390/cells10092227.
Immune Response in Infections According to the Host Immune System Status.
Charpentier E, Menard S, Marques C, Berry A, Iriart X
J Fungi (Basel). 2021; 7(8).
PMID: 34436164
PMC: 8399367.
DOI: 10.3390/jof7080625.
Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study.
Bavaro D, Pizzutilo P, Catino A, Signorile F, Pesola F, Di Gennaro F
Open Forum Infect Dis. 2021; 8(6):ofab187.
PMID: 34141817
PMC: 8204890.
DOI: 10.1093/ofid/ofab187.
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
Zhang Q, Tang L, Zhou Y, He W, Li W
Front Immunol. 2021; 12:663986.
PMID: 34122422
PMC: 8195248.
DOI: 10.3389/fimmu.2021.663986.
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.
Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll A, Tragiannidis A
J Fungi (Basel). 2021; 7(3).
PMID: 33807678
PMC: 7999508.
DOI: 10.3390/jof7030186.
Not COVID-19, Don't Overlook Pneumocystis in Patients on Gefitinib!.
Barben J, Quipourt V, Vovelle J, Putot A, Manckoundia P
Curr Oncol. 2021; 28(1):961-964.
PMID: 33617512
PMC: 7985782.
DOI: 10.3390/curroncol28010094.
Considerations for cancer immunotherapy during the COVID-19 pandemic.
Kanjanapan Y, Yip D
Med J Aust. 2020; 213(9):390-392.e1.
PMID: 33034044
PMC: 7675256.
DOI: 10.5694/mja2.50805.
Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity.
Lee K, Shaw H, Bataille V, Nathan P
J Immunother Cancer. 2020; 8(2).
PMID: 33020237
PMC: 7537329.
DOI: 10.1136/jitc-2020-000577.
Immune-related adverse events of checkpoint inhibitors.
Ramos-Casals M, Brahmer J, Callahan M, Flores-Chavez A, Keegan N, Khamashta M
Nat Rev Dis Primers. 2020; 6(1):38.
PMID: 32382051
PMC: 9728094.
DOI: 10.1038/s41572-020-0160-6.
